A Point Prevalence Survey of Antimicrobial Use in Second-Level Mexican Hospitals: A Multicenter Study.
German Alberto Venegas-Esquivel, Mar��a Guadalupe Berumen-Lechuga, Carlos Jos�� Molina-P��rez, Rodolfo Norberto Jimenez-Juarez, Enna Guadalupe Villanueva-Cabrera, David Vargas-Gonz��lez, Gonzalo Santos-Gonz��lez, Rebeca Pamela Vel��zquez P��rez, Mariana Hern��ndez Navarrete, Celene Corral-Rico, Natali Robles-Ordo��ez, Juan Manuel Lara-Hern��ndez, Helen's Irais S��nchez Mendoza
Author Information
German Alberto Venegas-Esquivel: Pediatric Department, Hospital de Ginecolog��a y Obstetricia 221, Instituto Mexicano del Seguro Social (IMSS), Toluca 50000, Mexico. ORCID
Mar��a Guadalupe Berumen-Lechuga: Medical Research Coordination, ��rgano de Operaci��n Administrativa Desconcentrada Regional Mexico Poniente, Instituto Mexicano del Seguro Social (IMSS), Toluca 50000, Mexico. ORCID
Carlos Jos�� Molina-P��rez: Health Research Division, Unidad M��dica de Alta Especialidad Hospitalde Ginecolog��a y Obstetricia No. 4, Instituto Mexicano del Seguro Social (IMSS), Mexico 01090, Mexico. ORCID
Rodolfo Norberto Jimenez-Juarez: Infectious Diseases Departament, Federico G��mez Children's Hospital of Mexico, Mexico City 06720, Mexico.
Enna Guadalupe Villanueva-Cabrera: Resident Emergency Departament, Hospital General Regional No. 251, Instituto Mexicano del Seguro Social (IMSS), Metepec 52148, Mexico. ORCID
David Vargas-Gonz��lez: Resident Emergency Departament, Hospital General de Zona n��mero 194, Instituto Mexicano del Seguro Social (IMSS), El Molinito 53000, Mexico. ORCID
Gonzalo Santos-Gonz��lez: Resident General Surgery Department, Hospital General Regional 251, Instituto Mexicano del Seguro Social, Metepec 52104, Mexico. ORCID
Rebeca Pamela Vel��zquez P��rez: Social Service Intern, Education and Research Deparment, Hospital General de Zona 252, Instituto Mexicano del Seguro Social (IMSS), Atlacomulco 50450, Mexico. ORCID
Mariana Hern��ndez Navarrete: Social Service Intern, Education and Research Deparment, Hospital General de Zona 252, Instituto Mexicano del Seguro Social (IMSS), Atlacomulco 50450, Mexico. ORCID
Celene Corral-Rico: Neonatology Departament, Hospital para el Nino, Instituto Materno Infantil del Estado de Mexico, Toluca 50170, Mexico.
Natali Robles-Ordo��ez: Infectious Diseases Department, Hospital para el Nino, Instituto Materno Infantil del Estado de Mexico, Toluca 50170, Mexico.
Juan Manuel Lara-Hern��ndez: Intensive Care Department, Hospital de Ginecolog��a y Obstetricia 221, Instituto Mexicano del Seguro Social (IMSS), Toluca 50000, Mexico.
Helen's Irais S��nchez Mendoza: Medical School, Autonomous University of the State of Mexico, Toluca 50180, Mexico. ORCID
In 2018, the WHO published a methodology for conducting a point prevalence survey (PPS) of antibiotic use in hospitals. The aim of this study is to report the use of antibiotics in six second-level hospitals in Mexico using this methodology. Methods: A multicenter cross-sectional study based on the 2021-2023 adaptation for Latin American hospitals was conducted in internal medicine, surgery, intensive care unit (ICU), obstetrics and gynecology and pediatrics departments of the IMSS in the western region of the state of Mexico. Results: The overall prevalence of antibiotic use was 61%; the services with the highest prevalence of prescription were general surgery (79%) and the ICU (78%). A total of 846 patients were surveyed; there were no differences in antibiotic use or non-use in terms of gender, surgical procedure and invasive devices, but there were differences in median age and comorbidities. Adherence to guidelines was 53.9%. The three main antibiotics used were third-generation cephalosporins (28%), carbapenems (13%) and glycopeptides (9%); for the type of indication, for CAI and prophylaxis, the rates of use of third-generation cephalosporins were 29.2% and 44.5%, respectively, while for healthcare-associated infections, carbapenems were used (23.9%). By AWaRe group, the watch group was predominant for all types (63.9%), for prophylaxis it was the access group (39.3%), and for HAIs it was the reserve group (4.9%).
